FDA approves Keytruda for adjuvant NSCLC, a Merck catalyst
100% citation coverage3 regulatory sources
Merck keytruda price is a relevant watch item after the FDA’s January 26, 2023 approval of pembrolizumab for adjuvant treatment of resected early-stage NSCLC. The catalyst expands Keytruda’s lung cancer footprint and gives BD teams, investors, and analysts a dated regulatory milestone to track.
Intelligence Snapshot
Executive Summary
On January 26, 2023, the FDA approved pembrolizumab (Keytruda) as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer after resection and platinum-based chemotherapy.
Key Insights
-
On October 16, 2023, the FDA approved pembrolizumab in combination with…
On October 16, 2023, the FDA approved pembrolizumab in combination with platinum-containing chemotherapy as a neoadjuvant treatment for non-small cell lung cancer.
- Pembrolizumab is a PD-1 inhibitor manufactured by Merck Sharp & Dohme LLC.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Loading intelligence…
Loading intelligence…
Quick Answer
On January 26, 2023, the FDA approved pembrolizumab (Keytruda) as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer after resection and platinum-based chemotherapy.
Key Questions
- What changed on January 26, 2023?
- Who is affected by this approval?
- What happened in October 2023?
- What should teams watch next?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for pembrolizumab.
Unlock full calendar →Merck & Co. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Contents16 sections
FDA approves Keytruda for adjuvant NSCLC, a Merck catalyst
Merck keytruda price is a relevant watch item after the FDA's January 26, 2023 approval of pembrolizumab for adjuvant treatment of resected early-stage NSCLC. The catalyst expands Keytruda's lung cancer footprint and gives BD teams, investors, and analysts a dated regulatory milestone to track.
IntelligenceRegulatory Impact
FDA decisions frame this story. Regulatory relevance is high for lung cancer, with pembrolizumab and Keytruda most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- On January 26, 2023, the FDA approved pembrolizumab (Keytruda) as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer after resection and platinum-based chemotherapy.
- On October 16, 2023, the FDA approved pembrolizumab in combination with platinum-containing chemotherapy as a neoadjuvant treatment for non-small cell lung cancer.
- Pembrolizumab is a PD-1 inhibitor manufactured by Merck Sharp & Dohme LLC.
IntelligenceCompetitive Intelligence
Merck & Co. are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.
The Regulatory Event
On January 26, 2023, the FDA approved pembrolizumab (Keytruda; Merck), a PD-1 inhibitor, as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC), after resection and platinum-based chemotherapy. The approval extends Keytruda's label into the post-operative setting for resected disease, establishing a new treatment use after surgery and chemotherapy completion.
Pembrolizumab, manufactured by Merck Sharp & Dohme LLC, is a programmed death receptor-1 (PD-1)-blocking antibody. The adjuvant indication applies to consolidation treatment after surgery and platinum-based chemotherapy, positioning the drug in a distinct clinical setting from earlier metastatic and first-line uses.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for lung cancer. Expect implications for pricing, access, and launch sequencing.
Regulatory Context and Label Sequencing
Adjuvant immunotherapy approvals in NSCLC address patients after surgical resection who have received platinum-based chemotherapy. On October 16, 2023, the FDA approved pembrolizumab in combination with platinum-containing chemotherapy as neoadjuvant treatment for non-small cell lung cancer. This second approval extends the drug's use to the pre-operative setting as well, reflecting systematic label expansion across treatment sequencing in resectable NSCLC.
IntelligenceStrategic Takeaways
On January 26, 2023, the FDA approved pembrolizumab (Keytruda) as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer after resection and platinum-based chemotherapy. On October 16, 2023, the FDA approved pembrolizumab in combination with platinum-containing chemotherapy as a neoadjuvant treatment for non-small cell lung cancer. Pembrolizumab is a PD-1 inhi
Clinical Setting and Patient Population
The approved adjuvant indication applies to patients who have undergone complete surgical resection and received platinum-based chemotherapy. This positioning places Keytruda in a distinct clinical niche: patients with resected stage IB-IIIA disease who have completed standard chemotherapy and are eligible for consolidation immunotherapy. The dual regulatory events—adjuvant in January 2023 and neoadjuvant in October 2023—demonstrate systematic expansion of pembrolizumab across treatment sequencing in resectable NSCLC.
IntelligenceEvidence Quality
Grounded in 3 regulatory sources.
Implications for Pharma Teams
For BD teams, investors, and analysts, the January 2023 adjuvant approval provides a dated U.S. regulatory catalyst. The approval broadens Keytruda's use in early-stage lung cancer and establishes a benchmark for competitive positioning in adjuvant NSCLC. Tracking Merck keytruda price and coverage developments will help assess commercial uptake of the new indication.
The sequential approvals—adjuvant followed by neoadjuvant—show progression of pembrolizumab across multiple treatment settings within the lung cancer indication. These regulatory milestones are relevant reference points for investors monitoring Merck's oncology franchise expansion.
What to Watch Next
For investors and BD teams, several developments merit continued monitoring:
- Label follow-through and any additional regulatory updates for pembrolizumab in resectable NSCLC.
- Future regulatory actions in the adjuvant NSCLC space.
- How Merck frames the adjuvant indication in investor updates and clinical communications.
- Market adoption and payer coverage decisions related to the new adjuvant indication.
Drug Snapshot
| Drug | pembrolizumab |
|---|---|
| Generic name | PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH |
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] |
| Manufacturer | Merck Sharp & Dohme LLC |
| Route | SUBCUTANEOUS |
| Indication | 1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric patients 12 years and older with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with metastatic nonsquamous N |
Regulatory Summary
- Approved indication: 1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric patients 12 years and older with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with metastatic nonsquamous N
- pembrolizumab is_class Programmed Death Receptor-1 Blocking Antibody [EPC]
- Merck Sharp & Dohme LLC develops pembrolizumab
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07353957 | Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer | RECRUITING | PHASE2 | Merus B.V. |
| NCT05232409 | Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer | RECRUITING | PHASE1 | Valley Health System |
| NCT05379972 | Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | COMPLETED | PHASE2 | University of Colorado, Denver |
| NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | RECRUITING | PHASE3 | National Cancer Institute (NCI) |
| NCT07276399 | A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | RECRUITING | PHASE3 | Janssen Research & Development, LLC |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| National Cancer Institute (NCI) | lung cancer | 3 |
| Janssen Research & Development, LLC | lung cancer | 2 |
| Regina Elena Cancer Institute | lung cancer | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | lung cancer | 1 |
| Merus B.V. | lung cancer | 1 |
Timeline
- Recruiting trial NCT07353957 (PHASE2)
- Recruiting trial NCT05232409 (PHASE1)
- Recruiting trial NCT07198074 (PHASE3)
- Recruiting trial NCT07276399 (PHASE3)
- Recruiting trial NCT07353957 (PHASE2)
Frequently Asked Questions
What changed on January 26, 2023?
The FDA approved pembrolizumab (Keytruda) as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer after resection and platinum-based chemotherapy. This expands Keytruda's label to include a post-operative indication in NSCLC.
Who is affected by this approval?
The approval affects Merck's commercial strategy in NSCLC, oncology teams managing resected stage IB-IIIA patients, payers evaluating coverage, and investors tracking Keytruda's label expansion. BD teams evaluating regulatory progression in adjuvant immunotherapy should monitor this development.
What happened in October 2023?
On October 16, 2023, the FDA approved pembrolizumab in combination with platinum-containing chemotherapy as neoadjuvant treatment for non-small cell lung cancer. This approval extends Keytruda's use to the pre-operative setting, complementing the earlier adjuvant indication and broadening the drug's role in resectable NSCLC.
What should teams watch next?
Watch for label follow-through, any additional NSCLC regulatory actions, and how Merck frames the franchise in future updates. Monitoring market adoption and payer coverage decisions will help track commercial uptake of the adjuvant indication.
Related profiles
Related coverage
- FDA clears U.S. trial of MAIA lung cancer drug for third-line patients
- Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
- EU Draft Merger Guidelines: Capabilities Treatment Needs Revisiting
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About lung cancer
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow pembrolizumab developments
FDA lung cancer alerts and pembrolizumab pipeline updates, every Monday.
- Sources analyzed
- 3
- Evidence strength
- 99/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…